Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.

The invention relates to methods and kits for detecting a virus, e.g., a respiratory virus such as a coronavirus, in a biological sample. The invention also relates to methods and kits for detecting and/or quantifying biomarkers, e.g., antibody biomarkers against a viral antigen; inflammatory and/or tissue damage response biomarkers; and/or extracellular vesicles in response to a viral infection.

The disclosure provides methods for determining the presence of coronavirus neutralizing antibodies in a sample as well as associated compositions and kits. The methods of the disclosure use recombinant vesicular stomatitis virus (VSV) particles, wherein the VSV glycoprotein (G) is replaced by a coronavirus spike (S) glycoprotein or a fragment or a derivative thereof. In a specific embodiment, the S glycoprotein is derived from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and the methods are used for determining the presence of SARS-CoV-2 neutralizing antibodies.

The current disclosure provides compositions, methods, and kits for detecting the exposure to and infection by certain viruses. Specifically, the current disclosure allows for the rapid differential serological detection of exposure to, and infection by viruses. In particular, the current disclosure allows for the rapid differential serological detection of exposure to, and infection by corona virus (SARS-CoV-2). The current disclosure provides for peptides for the differential detection of SARS-CoV-2.

Disclosed herein, are recombinant polypeptides comprising a first domain, wherein the first domain comprises an epitope of a coronavirus or wherein the first domain is a moiety that is capable of specifically binding a coronavirus antigen; a linker; and a second domain, wherein the second domain is a moiety that is capable of specifically binding an antigen on the surface of a red blood cell. Also, disclosed herein are methods for detecting anti-coronavirus antibodies, one or more coronavirus antigens, or one or more coronavirus virions by mixing the recombinant polypeptide with red blood cells and anti-coronavirus antibodies resulting in visible agglutination.

The present disclosure provides methods of detecting mycobacterium in an individual, generally involving detecting antibody to a mycobacterial lipid in a biological sample obtained from the individual. The present disclosure further provides compositions and kits for carrying out the methods.

The present application provides stable peptide-based antibody capture agents and methods of use as detection and diagnosis agents. The application further provides methods of manufacturing antibody capture agents using iterative on-bead in situ click chemistry.

Compositions and immunoassays for detecting SARS-CoV-2 antigen-specific antibodies in a biological sample are provided. The compositions are antigens from SARS-CoV-2 such as the proteins N, M, S, S1, S2′, NSP1, ORF3a, ORF3b, ORF7a, ORF7b and ORF8, fused to a light emitting protein. The compositions are useful in immunoassays for detecting antibodies to the SARS-CoV-2 antigens. A preferred immunoassay is the luciferase immunoprecipitation systems (LIPS) to detect SARS-CoV-2 antigen-specific antibodies with high sensitivity and specificity. The current or present exposure or infection with SARS-CoV-2 can be detected and/or diagnosed using the disclosed compositions and methods. Typically, the presence and/or elevated amount of SARS-CoV-2 antibodies in the individual’s biological sample compared to a control is indicative of current or past exposure or infection with SARS-CoV-2 as discussed herein.

The present disclosure provides materials and methods for identifying patients that are at risk of progression to clinically significant COVID-19 infection or disease.

Provided herein are protein biosensors, fusion proteins, compositions, and methods that are useful in detecting SARS-CoV-2 viruses in a sample from a subject. The viral detection assays described herein are solution-based, rapid, and quantitative. The protein biosensors and fusion proteins herein are able to bind to SARS-CoV-2 viral proteins. Use of the fusion proteins in proximity assays (e.g., split reporter assays) allows sensitive detection of SARS-CoV-2 virus in samples.